摘要：

Several monoclonal antibodies have been developed to target molecules in the inflammatory pathways of asthma. Lebrikizumab was developed to bind and inhibit IL-23 (7). Periostin, a matricellular protein, is secreted by bronchial epithelial cells in response to IL-13 and is a surrogate marker of IL-13 activity (8). Its function is largely unknown, but periostin has been associated with bronchial subepithelial fibrosis and regulation of mucous production in asthma (8, 9).A randomized, double-blind, placebo-controlled, parallel-group multicenter study evaluated the response of patients with moderate to severe asthma treated with lebrikizumab (7). A total of 219 patients received either 250 mg of lebrikizumab subcutaneously or placebo monthly for 6 months. Subgroups based on high or low periostin levels were defined. The primary efficacy outcome was the relative change in prebronchodilator FEVi from baseline at Week 12.

展开